Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

Avastin increases tumor response rates in breast cancer patients before surgery

Avastin increases tumor response rates in breast cancer patients before surgery

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Possible new drug targets for treating diffuse large B-cell lymphoma

Possible new drug targets for treating diffuse large B-cell lymphoma

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

EC grants marketing authorization for BENLYSTA to treat SLE

EC grants marketing authorization for BENLYSTA to treat SLE

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Transplants with half-matched bone marrow or cord blood are comparable to fully matched tissue

Half-matched transplants widen donor pool for leukemia and lymphoma

Half-matched transplants widen donor pool for leukemia and lymphoma

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

FDA grants Orphan Drug Designation for Accentia's Revimmune to treat two autoimmune diseases

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphoma

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

Initial data from COMPLETE study on peripheral T-cell lymphoma presented at ICML 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

Initial positive results from ZIOPHARM's ZIN-CTI-001 Phase Ib study against advanced melanoma

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011